funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
United States
HQ address
1303 E University Blvd #20701, Tucson, 85719, USA
Anivax is the global leader in the development of a vaccine to reduce the incidents of Campylobacter (Campy) jejuni in chickens. Jejuni naturally colonises the digestive tract of bird species, including chickens consumed by humans.

Campylobacter is one of the two most common causes of foodborne diarrheal sicknesses, surpassing Salmonella, and causing an estimated 1.3 million human health related cases annually. Campylobacter results in over $5.6 billion in healthcare costs each year in the U.S. alone.

Guillain-Barré syndrome (GBS) is an autoimmune reaction that can cause acute neuro-muscular paralysis. Of an estimated 2,628 to 9,575 new U.S. cases with GBS annually, 526 to 3,830 are triggered by infection with Campylobacter. Although there are several different triggering factors for GBS, no single factor appears to cause a greater proportion of GBS cases than does Campylobacter.

Successful vaccination of chickens would lead to compliance with the new USDA performance standards for Campylobacter in chickens, resulting in significant reduction of human illnesses. The Anivax Team has unique knowledge associated with the vaccine.

Anivax’s Campylobacter vaccine has been developed through research at the University of Arizona and Arizona State University, including USDA and institutional funding. The vaccine is ready to move into conditional market use in poultry and is positioned for unrestricted market deployment in the next 18 months with significant domestic and global benefits.

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats